U.S. Markets close in 2 mins

Galera Therapeutics, Inc. (GRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.88-0.09 (-1.29%)
As of 4:00PM EDT. Market open.

Galera Therapeutics, Inc.

2 West Liberty Boulevard
Suite 100
Malvern, PA 19355
United States
610 725 1500
http://www.galeratx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees38

Key Executives

NameTitlePayExercisedYear Born
Dr. J. Mel SorensenCEO, Pres & Director571.33kN/A1957
Dr. Robert A. BeardsleyCo-Founder & COO456.03kN/A1961
Mr. Christopher DegnanCFO & Sec.169.74kN/A1980
Mr. Joel F. SussmanChief Accounting Officer & TreasurerN/AN/A1949
Dr. Dennis P. Riley Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Jon T. HolmlundChief Medical OfficerN/AN/A1957
Mr. Arthur J. FratamicoChief Bus. OfficerN/AN/A1966
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Corporate Governance

Galera Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.